Published in:
01-09-2019 | Hepatitis B | Hepatitis B (JK Lim, Section Editor)
Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection
Authors:
Mike T. Wei, Mindie H. Nguyen, Ramsey Cheung
Published in:
Current Hepatology Reports
|
Issue 3/2019
Login to get access
Abstract
Purpose of Review
Chronic hepatitis B (CHB) and treatment may be associated with increased risk of osteopenia/osteoporosis. Here, we review the prevalence of osteopenia/osteoporosis among patients with CHB and the effect of antiviral therapy on bone density. We also highlight screening and management strategies for bone disease among patients with CHB.
Recent Findings
While there are concerns with first-line antiviral therapy such as tenofovir disoproxil fumarate in the development of osteopenia/osteoporosis, the available data remain rather unclear. However, with the development of tenofovir alafenamide, these concerns may be mitigated. At present, EASL recommends dual-energy X-ray absorption (DEXA) scans for patients with osteoporotic risk factors, with a repeat DEXA scan based upon baseline findings.
Summary
Patients with CHB have higher incidence and prevalence of osteopenia/osteoporosis compared with patients without CHB. Further studies are needed to understand the impact of antiviral therapy on bone therapy, and more CHB specific recommendations are needed for bone health management.